First experience of effectiveness and safety of bedaquiline for 18 months within an optimised regimen for XDR-TB

European Respiratory Journal

Volumn 47, Issue 5, 2016, Pages 1581-1584

  Lewis, Joseph M ^a,b   Hine, Paul ^a   Walker, Jenny ^c   Khoo, Sayeh ^b   Taegtmeyer, Miriam ^d   Squire, S Bertel ^d   Sloan, Derek J ^d,e  

^a ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c North Liverpool Community Health   (United Kingdom)

^d LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

^e LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; AZITHROMYCIN; BEDAQUILINE; CLOFAZIMINE; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; LINEZOLID; PYRAZINAMIDE; RIFAMPICIN; QUINOLINE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; GENE MUTATION; GENE SEQUENCE; HUMAN; KATG GENE; LETTER; LUNG TUBERCULOSIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QTC INTERVAL; RPOB GENE; SPUTUM CULTURE; SPUTUM SMEAR; T WAVE INVERSION; TREATMENT DURATION; YOUNG ADULT; DRUG ADMINISTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; SAFETY;

DIARYLQUINOLINES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; SAFETY; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84969760172     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01980-2015     Document Type: Letter

References (15)

1. Pietersen E, Ignatius E, Streicher EM, et al. Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: A cohort study. Lancet 2014; 383: 1230-1239.
2. Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2014; 371: 723-732.
3. Guglielmetti L, Le Du D, Jachym M, et al. Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis 2015; 60: 188-194.
4. Catho G, Couraud S, Grard S, et al. Management of emerging multidrug-resistant tuberculosis in a low-prevalence setting. Clin Microbiol Infect 2015; 21: 472.e7-e472.e10.
5. Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J 2014; 43: 289-292.
6. van Halsema C, Humphreys S, Bonington A. Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient. Eur Respir J 2014; 43: 292-294.
7. Danckers M, Lesko MB, Adamson R, et al. Compassionate use of bedaquiline in the treatment of pulmonary XDR-TB. Int J Tuberc Lung Dis 2014; 18: 1522-1523.
8. Udwadia ZF, Amale RA, Mullerpattan JB. Initial experience of bedaquiline use in a series of drug-resistant tuberculosis patients from India. Int J Tuberc Lung Dis 2014; 18: 1315-1318.
9. Ndjeka N, Conradie F, Schnippel K, et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: An interim cohort analysis. Int J Tuberc Lung Dis 2015; 19: 979-985.
10. Mase S, Chorba T, Lobue P, et al. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis. MMWR 2013; 62: 1-12.
11. World Health Organization. Companion Handbook to the WHO Guidelines for the Programmatic Management of Drug-Resistant Tuberculosis. Geneva, WHO, 2014.
12. Falzon D, Jaramillo E, Schunemann HJ, et al. WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. Eur Respir J 2011; 38: 516-528.
13. Pontali E, Sotgiu G, D'Ambrosio L, et al. Bedaquiline and multidrug-resistant tuberculosis: A systematic and critical analysis of the evidence. Eur Respir J 2016; 47: 394-402.
14. Aung KJM, Van Deun A, Declercq E, et al. Successful "9-month Bangladesh regimen" for multidrug-resistant tuberculosis.
15. IUALTD, Inc. The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients with MDR-TB (STREAM). https://clinicaltrials.gov/ct2/show/record/NCT02409290 Date last accessed: July 16, 2015. Date last updated: April 3, 2015.